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Abstract
Background: Opportunistic infections (OIs) are the leading cause of morbidity and mortality among children living
with human immunodeficiency virus (HIV). For better treatments and interventions, current and up-to-date
information concerning occurrence of opportunistic infections in HIV-infected children is crucial. However, studies
regarding the incidence of common opportunistic infections in HIV-infected children in Ethiopia are very limited.
Hence, this study aimed to determine the incidence of opportunistic infections among HIV-infected children on
antiretroviral therapy (ART) at Debre Markos Referral Hospital.
Methods: A facility-based retrospective cohort study was undertaken at Debre Markos Referral Hospital for the
period of January 1, 2005 to March 31, 2019. A total of 408 HIV-infected children receiving ART were included. Data
from HIV-infected children charts were extracted using a data extraction form adapted from ART entry and follow-
up forms. Data were entered using Epi-data™ Version 3.1 and analyzed using Stata™ Version 14. The Kaplan Meier
survival curve was used to estimate the opportunistic infections free survival time. Both bi-variable and multivariable
Cox proportional hazard models were fitted to identify the predictors of opportunistic infections.
Results: This study included the records of 408 HIV-infected children-initiated ART between the periods of January
1, 2005 to March 31, 2019. The overall incidence rate of opportunistic infections during the follow-up time was 9.7
(95% CI: 8.13, 11.48) per 100 child-years of observation. Tuberculosis at 29.8% was the most commonly encountered
OI at follow-up. Children presenting with advanced disease stage (III and IV) (AHR: 1.8, 95% CI: 1.2, 2.7), having “fair”
or “poor” ART adherence (AHR: 2.6, 95% CI: 1.8, 3.8), not taking OI prophylaxis (AHR:1.6, 95% CI: 1.1, 2.4), and CD4
count or % below the threshold (AHR:1.7, 95% CI: 1.1, 2.6) were at a higher risk of developing opportunistic
infections.
Conclusions: In this study, the incidence rate of opportunistic infections among HIV-infected children remained
high. Concerning predictors, such as advanced disease stage (III and IV), CD4 count or % below the threshold, “fair”
or “poor” ART adherence, and not taking past OI prophylaxis were found to be significantly associated with OIs.
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Background
The epidemic of Human Immunodeficiency Virus (HIV)
remains a serious public health concern [1]. In 2018, an
estimated 37.9 million people globally were living with
HIV, including 1.7 million children (aged < 15 years) [2].
Sub-Saharan Africa (SSA) is the most affected region [3]
with Ethiopia ranking within the top 25 countries with
the highest new HIV-infection rates [4]. Opportunistic
infections (OIs) are infections, which occur more fre-
quently and severely among individuals with weakened
immune systems, including People Living with Human
Immunodeficiency Virus (PLHIV) [5]. All HIV-infected
people are susceptible to develop a wide range of OIs
[6], but prevalence and incidence of HIV-associated OIs
vary widely [7, 8]. Most reports on the magnitude of OIs
in HIV-infected children are from North America and
Europe; while, in SSA, the true burden of OIs among
HIV-children remains poorly documented [9] .
OIs are the leading causes of morbidity and mortality
among HIV-infected children contributing to 94.1% of
HIV-related deaths [10–13]. Unless OIs are treated as
early as possible, they markedly affecting the treatment
outcomes of PLHIV leading to poor quality of life, has-
tening disease progression, increasing medical costs, po-
tentiating the risk of treatment failure, and impairing
patient’s response to antiretroviral therapy (ART) drugs
[14, 15]. In low and middle income countries, the most
frequently occurring OIs are tuberculosis (TB), oral can-
didiasis, varicella zoster, pneumocystis pneumonia, bac-
terial pneumonia, herpes zoster, and dermatophyte
infections [16, 17].
The World Health Organization (WHO) recommends
a range of medical interventions to reduce the occur-
rence of OIs among PLHIV. These interventions include
reduction of exposure, chemoprophylaxis (primary/sec-
ondary), immunization, and early initiation of ART [18].
The use of highly active antiretroviral therapy (HAART)
has been effective in reducing OIs significantly among
children and adolescents infected with HIV [19]. In
Ethiopia, the Ministry of Health (MOH) has been imple-
menting different interventions to improve the survival
of HIV infected individuals which is reflected, in part, in
the increased ART coverage from 5% in 2010 to 9.5% in
2013 [18, 20].
Despite the dramatic decline in the incidence OIs after
the introduction HAART, they remain a major cause of
morbidity and mortality among these vulnerable popula-
tion [21]. Most HIV-associated OIs and other co-
morbidities are easily preventable and treatable with safe
and cost-effective interventions. However, for better in-
terventions, information regarding the patterns and oc-
currences of OIs is essential for all age groups (especially
vulnerable populations such as children and pregnant
women), but are often absent for low and middle income
countries, including Ethiopia. Therefore, this study was
undertaken to determine the incidence of common OIs
among HIV-infected children at Debre Markos Hospital.
Results obtained from this study will potentially help
health professionals to develop a new strategy for the
prevention and management of OIs and inform a na-
tional program of research inclusive of interventional
studies.
Methods
Study design, setting, and period
A facility-based retrospective cohort study was con-
ducted at Debre Markos Referral Hospital. Debre Mar-
kos town is located 300 km far from Addis Ababa, the
capital city of Ethiopia and 265 km far from Bahir Dar,
the capital city of Amhara Region. According to the
2007 national census, Debre Markos has a total popula-
tion of 62,497, of whom 29,921 were men and 32,576
were women [22]. Debre Markos Referral Hospital is the
only referral hospital in East Gojjam Zone providing ser-
vices for more than 3.5 million peoples in the zone and
neighboring zones. The hospital has been providing
HIV-care and ART follow-up services since 2005. Cur-
rently, the ART clinic of this hospital has one medical
doctor, five nurses, three data clerks, one porter, one
cleaner, five case managers, and six adherence sup-
porters. The hospital uses standardized ART monitoring
and evaluation tools adapted from the Ethiopian national
comprehensive HIV care and treatment guidelines [18].
To date, a total of 466 HIV-infected children com-
menced ART at this site of which, approximately 350
HIV-infected children are receiving active ART follow-
up at the time of this study.
Study participants
The source population for this study were all HIV-
infected children (aged < 15 years) ever initiated on ART
at Debre Markos Referral Hospital, with the study popu-
lation including those HIV-infected children started on
ART between January 1, 2005 to March 31, 2019. HIV-
infected children who had incomplete baseline informa-
tion (CD4 count, hemoglobin level, WHO clinical stage,
weight and height) and/or who had OIs at the time of
ART initiation were excluded from the study.
Sampling procedures
The records of all HIV-infected children ever started on
ART (466) at Debre Markos Referral Hospital were re-
cruited. After excluding incomplete records, records of
408 HIV-infected children met the criteria and were in-
cluded in the study. Data were extracted from the charts
of 408 HIV-infected children on ART.
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Variables of the study
The dependent variable for this study was the occurrence
of any type of opportunistic infections during follow-up.
The independent variables included: Socio-demographic
characteristics (i.e., age, sex, residence, religion, marital
status of care giver, relationship of care giver, current sta-
tus of parents, occupation of the caregiver, and family
size); Clinical and laboratory predictors (i.e., WHO clinical
stage, CD4 count, hemoglobin (Hgb) level, underweight,
wasting, stunting, history of Prevention of Mother to
Child Transmission (PMTCT), prior history of OIs, func-
tional status, and developmental status); and ART and
other medication-related predictors (i.e., past OI prophy-
laxis, type of baseline ART regimen, ART eligibility cri-
teria, presence of regimen changed, level of ART
adherence, ever taking Isoniazid Preventive Therapy
(IPT), ART side effects, and ART treatment failure).
Operational definition of variables
In this study, an event was considered when HIV-
infected child developed any form of OIs after ART initi-
ation during the follow-up period.
Censored was recorded when HIV-infected children
dropped or transfer out (whether dead or alive) to other
health institutions or are still on active ART follow-up,
but did not develop any OIs by the end of the study.
ART adherence was classified as good, fair, or poor,
according to the percentage of drug dosage calculated
from the total monthly dose of ART drugs. Good was
reported with compliance equal to or greater than 95%
or ≤ 3 missed doses per month; fair reflected 85–94%
compliance and between 4 and 8 missing doses per
month); and poor reflected less than 85% compliance
or ≥ 9 missed dose per month) [23].
Child developmental status was classified as appropri-
ate (able to attain milestones for age), delayed (failure to
attain milestones for age); and regression (loss of what
has been attained for age) [18].
Children with weight/age Z-score < − 2 SD, height/age
Z-score < − 2 SD, and weight/height Z-score < − 2 SD
were considered to be underweight, stunted, and wasted
respectively [24, 25].
OIs are infections, which occur more frequently and
severely among individuals with weakened immune sys-
tems, including People Living with Human Immunodefi-
ciency Virus (PLHIV) [5]. According to the Ethiopian
ART guidelines, the common OIs include herpes zoster,
bacterial pneumonia, pulmonary TB, extra-pulmonary
TB, oral candidiasis, oesophageal candidiasis, mouth
ulcer, diarrhoea, pneumocystis pneumonia, central ner-
vous system toxoplasmosis, Cryptococcal meningitis,
non-Hodgkins lymphoma, Kaposi’s sarcoma, cervical
cancer, and others [18].
CD4 counts or percentage (%) below the threshold
was considered if the child had CD4 cell counts < 1500/
mm3 or 25% for age < 12months, CD4 cell counts < 750/
mm3 or < 20% for age 12–35 months, CD4 cell counts <
350/mm3 or < 15% for age 36–59 months, and CD4 cell
counts < 200/mm3 or < 15% for age ≥ 60 months [26].
Data collection procedures and quality assurance
The data extraction form was based on the federal Minis-
try of Health’s HIV-care/ART follow-up and intake forms,
which are used in the ART clinics of Ethiopian hospitals.
The data extraction form included the following variables:
socio-demographic characteristics, ART and other medi-
cation, clinical, and laboratory-related information. Data
were collected by three BSc prepared nurses working in
the ART clinic of Debre Markos Referral Hospital. To as-
sure data quality, a data extraction checklist was carefully
adapted from a standardized ART intake and follow up
forms, nurses currently work in the ART clinic and who
took ART training were recruited as data collectors, a
one-day training was given for both data collectors and
supervisors, completeness of the recorded variables were
double checked by taking some randomly selected cards,
and the supervisor as well as principal investigators care-
fully monitored the entire data collection process. Subse-
quently, all relevant data were retrieved through reviewing
of HIV-infected children’s cards. The occurrence of OIs
during data extraction was ascertained by reviewing the
health professionals’ reporting on patient charts. Any la-
boratory tests obtained at the time of ART initiation were
considered as a baseline data. However, if laboratory tests
were not done during ART initiation, any lab tests done
within a month of ART initiation were considered as the
baseline.
Data analysis
Before entry, data were checked for its completeness and
consistency. We used Epi-data™ Version 3.1 for data
entry and STATA™ Version 14 for data analysis. Besides,
Emergency Nutritional Assessment (ENA) and WHO
AnthroPlus software were used to analyze the nutritional
status (underweight [WAZ], stunting [HAZ] and wasting
[WHZ]) of HIV-infected children. Descriptive statistics
were summarized as percentage, mean, and median, and
visualized using tables and charts. The OIs free survival
time was estimated using the Kaplan-Meier survival
curve. Besides, the OIs free survival time between differ-
ent categorical explanatory variables were compared
using generalized log rank test. A life table was con-
structed to estimate probabilities of OIs at different time
intervals and cumulative survival probabilities. The com-
mon assumptions of Cox proportional hazard regression
model were checked using Schoenfeld residuals test. In
the bi-variable analysis, variables with p-values ≤0.25
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were selected for the multivariable analysis [27, 28]. In
the final model, variables with p-values < 0.05 were con-
sidered as statistically significant predictors of OIs.
Results
Socio-demographic characteristics of the cohort
A total of 466 HIV-infected children’s medical records
were retrieved. Of these, 58 were excluded from the ana-
lysis due to incompleteness. The remaining 408 HIV-
infected children on ART were included in this study. The
median age of the study participants was 7 years (IQR = 4,
10). About 42.9% of the children were in the age group of
5 to 9 years. Slightly more than half (54.7%) of the children
were male, and more than two thirds (72.1%) were from
urban areas. More than half (53.7%) of the parents were
both alive and the majority (85.3%) of children were living
with their biological parents (Table 1).
Clinical, laboratory and medication-related characteristics
About half (51.9%) of children were classified as WHO
clinical stage I and II and almost two third (67.9%) of
the children had CD4 counts or percentage (%) above
the threshold. About 10.3% of participants had < 10 mg/
dl hemoglobin level with a median of 12.3 (IQR = 11.3–
13.3) mg/dl, with 49.3, 23.8, and 51.7% of participants
being underweight, wasted and stunted respectively.
More than half (60.8%) of children had taken past OI
prophylaxis. Children exhibiting a good adherence level
to ART and nevirapine baseline ART regimens were
78.7 and 66.7%, respectively and 56.1% had no history of
PMTCT (Table 2).
Incidence of opportunistic infections during follow-up
The study participants were followed for a minimum of 2
months and a maximum of 132months. The total person
months of the cohort was 16, 024 child-months of obser-
vation. During the follow-up time, almost one third
(31.6%) of the study participants developed OIs. This
study found that the incidence rate of OIs among HIV-
infected children was 9.7 (95% CI: 8.1, 11.5) per 100 child-
years of observation. From all types of OIs occurring dur-
ing the follow-up time, TB (29.8%) was the most common,
followed by bacterial pneumonia (27.7%), and non-
Hodgkins lymphoma or Kaposi’s sarcoma (11.3%) (Fig. 1).
Table 1 Sociodemographic characteristics of HIV-infected children on ART at Debre Markos Referral Hospital, Northwest Ethiopia,
from January 1, 2005 to March 31, 2019 (N = 408)
Characteristics Category Frequency (N) Percentage (%)
Age of the child (years) 0–4 years 122 29.9
5–9 years 175 42.9
10–14 years 111 27.2
Sex Male 223 54.7
Female 185 45.3
Residence Urban 294 72.1
Rural 114 27.9
Family size 1–3 184 45.1
≥4 179 43.9
Not recorded 45 11.0
Current status of parents Both alive 219 53.7
One or both deceased 189 46.3
Marital status of the caregiver Married 172 42.0
Divorced/ widowed 167 41.0
Not recorded 69 17.0
Occupation of the caregiver Employed 86 21.3
Unemployed 203 50.3
Merchant 65 16.1
Not recorded 54 12.4
With whom the child lives Biological 348 85.3
Non-biological 60 14.7
Religion Orthodox 348 85.3
Muslim 21 5.1
Others 39 9.5
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Table 2 Baseline clinical, laboratory and medication-related characteristics of the HIV-infected children on ART at Debre-Markos
Referral Hospital, Northwest Ethiopia, from January 1, 2005 to March 31, 2019 (N = 408)
Characteristics Categories Frequency (N) Percentage (%)
History of PMTCT Yes 56 13.7
No 229 56.1
Not recorded 123 30.2
History of OIs Yes 215 52.7
No 193 47.3
Weight for age Normal 207 50.7
Underweight 201 49.3
Weight for height Normal 311 76.2
Wasted 97 23.8
Height for age Normal 197 48.3
Stunted 211 51.7
WHO clinical stage Stage I and II 212 52.0
Stage III and IV 196 48.0
CD4 counts or % Above the threshold 277 67.9
Below the thresheold 131 32.1
Hgb level ≥ 10 g/dl 366 89.7
< 10 g/dl 42 10.3
ART eligibility criteria Test and treat 67 16.4
CD4 or WHO staging 341 83.6
Type of regimen at baseline Nevirapine base 272 66.7
Efaveraze base 86 21.1
Protease inhibitor base 50 12.3
Ever taking IPT Yes 217 53.2
No 191 46.8
ART adherence Good 321 78.7
Fair/ poor 87 21.3
Past OI prophylaxis Yes 248 60.8
No 160 39.2
ART side effect Yes 19 4.7
No 389 95.3
Regimen change Yes 84 20.6
No 324 79.4
Treatment failure Yes 20 4.9
No 388 95.1
Functional status Working 153 53.3
Ambulatory 113 39.4
Bed ridden 21 7.3
Developmental status Appropriate 73 60.3
Delayed 41 33.9
Regressed 7 5.8
PMTCT Prevention of Mother To Child Transmission, OIs Opportunistic Infections, WHO World Health Organization, Hgb Hemoglobin, CD4 Cluster of differentiation
4, and ART Antiretroviral Therapy
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Opportunistic infections free survival time of HIV-infected
children on ART
In this study, the median OIs-free survival time was 103
months (IQR = 30,128). Additionally, children presenting
with WHO clinical stage III and IV during ART initiation
had less OIs free survival time when compared to children
presenting in WHO stages I and II (Fig. 2). Figure 3 shows
that the OIs free survival time of children presenting with
severe immunodeficiency (CD4 count or %bellow the
threshold) was lower than those children with mild im-
munodeficiency (CD4 count or % above the threshold).
Moreover, children who had “fair or poor” ART drug ad-
herence had less OIs free survival time as compared to
those who had good ART drug adherence (Fig. 4). Further-
more, children who did not take past OI prophylaxis had
less OIs free survival time as compared to the past OI
prophylaxis user cohort (Fig. 5).
Predictors of OIs among HIV-infected children on ART
Weight for age Z-scores, history of past OIs, Hgb levels,
WHO clinical staging, CD4 counts or %, taking past OI
prophylaxis, ever taking IPT, and ART drug adherence were
variables for multivariable analysis Of these, WHO clinical
staging, CD4 counts, ART drug adherence, and past OIs
prophylaxis were found to be significant predictors of OIs.
Children presenting with WHO clinical stage III and IV
were nearly 2 times (AHR (adjusted hazard ratio): 1.8, 95%
CI: 1.2, 2.7) more likely to develop OIs as compared to
those children in WHO clinical stages I and II. This study
also found that HIV-infected children on ART who had
“fair” or “poor” ART adherence were 2 and half fold (AHR:
2.6, 95% CI: 1.8, 3.8) more likely to develop OIs as com-
pared to those children who had “good” ART adherence.
The risk of developing OIs among children with CD4 count
or % below the threshold was 1.7 times (AHR: 1.7, 95% CI:
1.1, 2.6) higher as compared to those children with CD4
counts or % above the threshold. Lastly, the risk of develop-
ing OIs among children who did not previously take OI
prophylaxis was 1.6 times (AHR: 1.6, 95% CI: 1.1, 2.4)
higher to those who took past OI prophylaxis (Table 3).
Discussion
This facility-based retrospective cohort study was under-
taken to determine the incidence of common OIs among
HIV-infected children on ART at Debre Markos Referral
Hospital. Almost one third (31.6%) of the study partici-
pants developed OIs, yielding an incidence rate of OIs
9.7 (95% CI: 8.1, 11.5) per 100 child-years of observation.
This finding is comparable with an Asian-based study
reporting 10.5 per 100 person-years [21]. Similarly, our
finding is much higher than studies from the United
States of America (4.99 per 100 person-years) [29], Latin
America (1.1 per 100 person-years) [30], and Brazil (2.63
per 100 person-years) [10].
Literature also showed that HIV-related OIs remain
high in resource limited settings; especially with SSA being
disproportionately affected [9]. Developed countries have
advanced technologies for early diagnosis, prevention, and
Fig. 1 Common types of OIs during follow-up time among HIV-infected children at Debre Markos Referral Hospital from 2005 to 30th
March, 2019
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Kaplan-Meier survival curves to compare the OIs-free survival time by WHO staging
Fig. 2 Kaplan-Meier survival curves to compare the OIs-free survival time of HIV-infected children on ART with different categories of WHO clinical
stages at Debre-Markos Referral Hospital from 2005 to 30th March, 2019
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Fig. 3 Kaplan-Meier survival curves to compare the OIs-free survival time of HIV-infected children on ART with different categories of CD4 counts
or % at Debre-Markos Referral Hospital from 2005 to 30th March, 2019
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management of OIs. Additional explanations for the above
noted discrepancies might be attributed to the lack of
awareness among HIV-infected peoples living in develop-
ing countries to take ART medications and OIs prophy-
laxis continuously [31]. Poverty, overcrowding, and
malnutrition are common problems in developing
countries, which could contribute to the higher occur-
rence of OIs among HIV-infected people.
Among all types of OIs, TB is the most common
(29.8%) during the follow-up time. This finding is consist-
ent with a study conducted in India, which documented
that TB is the most (34.6%) commonly diagnosed OI
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Fig. 4 Kaplan-Meier survival curves to compare the OIs-free survival time of HIV-infected children on ART with different categories of ART drug
adherence at Debre-Markos Referral Hospital from 2005 to 30th March, 2019
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Kaplan-Meier survival curves to compare the OIs-free survival time by OI prophylaxis
Fig. 5 Kaplan-Meier survival curves to compare the OIs-free survival time of HIV-infected children on ART with different categories of OI
prophylaxis at Debre-Markos Referral Hospital from 2005 to March 2019
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among HIV-infected individuals [32].However, studies re-
ported from Latin America [16, 17, 29] revealed that bac-
terial pneumonia is the most commonly diagnosed OI [33,
34]. A study done in India illustrated that pulmonary TB
was the most common opportunistic infection and
accounted for 26% of all OI cases [35]. PLHIV are 20 to
37 times more likely to develop TB as compared to the
general population [18]. Besides, Cryptococcal meningitis
accounted for 5.7% of OIs among HIV-infected children
on ART at Debre Markos Referral Hospital. This is also
an important finding since Cryptococcus neoformans is
not a common cause of meningitis in children.
In this study, children who started ART as WHO clin-
ical stage III and IV were more likely to develop OIs as
compared to those children who started ART as WHO
stage I and II. This finding aligns with studies done in
India [36, 37], and Asia [21]. OIs tend increase in number
and severity in alignment with WHO clinical disease
Table 3 The bi-variable and multivariable Cox-regression analysis of the predictors of OIs among HIV-children on ART at Debre-
Markos Referral Hospital, Northwest Ethiopia from January 1, 2005 to March 31, 2019 (N = 408)
Variables Events Censored CHR (95% CI) AHR (95% CI)
Age (years)
0–4 years 36 86 1 1
5–9 years 63 112 1.5 (0.98, 2.3) 1.2 (0.8, 1.9)
10–14 years 30 81 1.7 (1.03, 2.9) 1.4 (0.8, 2.4)
Current status of parents
Both alive 59 160 1 1
One or both dead 70 119 1.3 (0.9, 1.8) 1.0 (0.7, 1.5)
History of OIs
No 45 148 1 1
Yes 84 131 1.8 (1.3, 2.6) 1.2 (0.8, 1.83)
Weight for age Z-score
Normal weight 55 152 1 1
underweight 74 127 1.4 (1.0, 2.0) 1.1 (0.7, 1.6)
Height for age Z-score
Normal 56 141 1 1
Stunted 73 138 1.3 (0.9, 1.9) 0.8 (0.5, 1.1)
WHO clinical stage
Stage I and II 41 176 1 1
Stage III and IV 88 103 2.9 (2.0, 4.1) 1.8 (1.2, 2.7)a
CD4 counts or %
Above the threshold 60 217 1 1
Below the thresheold 69 62 3.3 (2.3, 4.6) 1.7 (1.1, 2.6)a
Hgb level
≥ 10 g/dl 109 257 1 1
< 10 g/dl 20 22 1.7 (1.1, 2.8) 1.0 (0.6, 1.7)
Ever taking IPT
Yes 64 162 1 1
No 65 117 1.9 (1.3, 2.7) 1.2 (0.8, 1.7)
ART adherence
Good 65 252 1 1
Fair/poor 64 27 3.7 (2.6, 5.2) 2.6 (1.8–3.8)a
Past OI prophylaxis
Yes 51 204 1 1
No 78 75 2.8 (2.0, 4.0) 1.6 (1.1, 2.4)a
asignificant predictors
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staging [36]. WHO clinical stages and OIs have a positive
association [37], such that HIV-infected individuals with
WHO clinical stage III and IV often exhibit severe im-
mune deficiency [38]. The level of immunity determines
the occurrence and type of OIs [18]. Therefore, as the
WHO clinical stage becomes more advanced the occur-
rence and recurrence of OIs also increase. The most ser-
ious and life threatening OIs become more common
among HIV-infected peoples with stage III and IV.
This study also found that ART drug adherence is an
important predictor for OIs. Children who had “fair or
poor” ART drug adherence were more likely to develop
OIs as compared to those who had good ART drug ad-
herence. A study conducted in Cameron found that
HIV-infected patients who were not adhered to the ART
therapy were more prone to develop OIs. This study also
documented that OIs significantly increased the risk of
non-adherence [39].
HIV-infected children with CD4 count or % below the
threshold at the time of ART initiation were more likely
to develop OIs as compared to those children with CD4
counts or % above the threshold). A 10 year retrospect-
ive study conducted in Uganda [40] documented that
the occurrence of OIs in patients with lower CD4 cell
counts at ART start was significantly high. Similar stud-
ies conducted in India [32, 36], Latin America [29, 30,
41], and Asia [21] showed that low CD4 counts during
ART enrollment significantly increased the risk of devel-
oping OIs. A study from the United States of America
revealed that children who had a CD4 percentage of less
than 15% at ART initiation were at higher risk of OIs
compared to those children who had an on initiation
CD4 percentage at or greater than 25% [29]. CD4 cells
are a type of white blood cells, which help to activate
other white blood cells in the immune system. There-
fore, any factors which reduce the number of CD4 cells
will impair the immune system of HIV-infected children
exposed to the development of OIs [42].
Lastly, this study found that the risk of developing
OIs among HIV-infected children who took past OI
prophylaxis was low as compared to those HIV-
infected children who did not take past OI prophy-
laxis. Previous Ethiopian studies revealed that prophy-
laxis has a significant effect in reducing the
occurrence of TB [43–45]. Another supportive finding
was documented in Latin America [30]. Cotrimoxa-
zole preventive therapy (CPT) is a feasible, cost-
effective, and safe way intervention to reduce HIV/
AIDS related morbidities and mortalities associated
with OIs [45]. Furthermore, the Ethiopian ART guide-
line recommends early initiation of CPT among HIV-
infected children benefited for the prevention of OIs
like pneumocystis pneumonia, bacterial infections,
toxoplasmosis gondii, diarrhea and other protozoal
infections; IPT to address latent TB, and fluconazole
for prevention of fungal and cryptococcal infections
[18].
Limitations of the study
The current study has some limitations, which must be
considered before interpreting results. The data for this
study was obtained from charts of HIV-infected children.
Therefore, we were unable to get some variables includ-
ing viral load, income, micronutrient deficiency, and
immunization status of the children. At times, OIs
might be underestimated due to excluded charts with
incomplete data and unrecorded by health professions.
Although the data are not always complete, the longitu-
dinal data set may have corrected for some of these
limitations.
Conclusions
In this study, the incidence rate of opportunistic infec-
tions among HIV-infected children remained high. Con-
cerning predictors such as advanced disease stage (III
and IV), CD4 count or % below the threshold, “fair” or
“poor” ART adherence, and not taking past OI prophy-
laxis were found to be significantly associated with OIs.
Therefore, based on the above findings, we recommend
consideration should be given to early screening and
treatment of OIs. Besides, adherence support through
phone calls and case managers could be strengthened.
Furthermore, children presented with severe immuno-
deficiency and advanced disease stage during the ART
initiation should be closely monitored and deeply inves-
tigated for the occurrence of OIs in each successive
follow-up.
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